2023-11-14T16:01:17-06:00 2022-12-31 113066459 CERINI & ASSOCIATES LLP 3340 VETERANS MEMORIAL HWY BOHEMIA NY 11716 990 2022-01-01 272417202 EB RESEARCH PARTNERSHIP INC EBRE 6468440902 244 MADISON AVENUE 104 NEW YORK NY 10016 MICHAEL HUND CEO 6468440902 2023-11-14 1 MICHAEL HUND 999009999 0 TANIA QUIGLEY P01549343 6315821600 2023-11-13 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z MICHAEL HUND 244 MADISON AVENUE 104 NEW YORK NY 10016 6661234 0 X WWW.EBRESEARCH.ORG X 2010 NY TO FUND RESEARCH FOR TREATMENTS AND A CURE FOR EPIDERMOLYSIS BULLOSA. 31 31 7 34 0 0 7177252 6106138 250000 0 9574 283333 299228 60974 7736054 6450445 2610877 5371260 0 0 789380 707329 0 0 1060534 662263 943238 4062520 7021827 3673534 -571382 20862871 22585702 2304352 4598565 18558519 17987137 EB RESEARCH PARTNERSHIP IS THE LARGEST ORGANIZAION DEDICATED TO FUNDING RESEARCH FOR TREATMENTS AND A CURE FOR EPIDERMOLYSIS BULLOSA, A GROUP OF DEVASTATING AND LIFE THREATENING GENETIC SKIN DISORDERS THAT AFFECT CHILDREN FROM BIRTH. 0 0 5683281 5371260 GRANTS AND MONEY AWARDED FOR FURTHER RESEARCH. EB RESEARCH PARTNERSHIP FUNDS THE MOST PROMISING, INNOVATIVE AND POTENTIALLY COMMERCIALLY VIABLE TREATMENTS AND POTENTIAL CURES FOR EB. OUR RESEARCH GRANTS INCORPORATE ADVANCES THROUGH THE FIELD OF BIOMEDICINE FOR BETTER TREATMENTS FOR ALL EB SUBTYPES. OUR SCIENTIFIC ADVISORY BOARD REVIEWS ALL GRANT APPLICATIONS SO THAT WE ARE ASSURED THAT GRANTS ARE RELEVANT, INNOVATIVE AND COULD MEANINGFULLY IMPROVE THE QUALITY OF LIFE FOR THOSE LIVING WITH EB. 5683281 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 0 1 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 11 0 1 7 1 0 1 AS 0 0 0 0 0 0 0 0 0 0 X 31 31 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NC NH NJ NM NY OR PA RI SC TN UT VA WI WV X X THE ORGANIZATION 6468440902 244 MADISON AVENUE 104 NEW YORK NY 10016 ALEXANDER J SILVER CHAIRMAN 5.00 X X 0 0 0 JILL VEDDER VICE CHAIRMAN 2.00 X X 0 0 0 JAMIE G SILVER SECRETARY 3.00 X X 0 0 0 EDWARD GROSSMANN TREASURER 1.00 X X 0 0 0 ABBIE LEVINE DIRECTOR 1.00 X 0 0 0 ALEXANDER LEMOS DIRECTOR 1.00 X 0 0 0 ARI DESHE DIRECTOR 1.00 X 0 0 0 CHAD CERETTO DIRECTOR 2.00 X 0 0 0 DANIEL DESHE DIRECTOR 1.00 X 0 0 0 EILEEN ATTAR DIRECTOR 1.00 X 0 0 0 ELEANOR DEHONEY DIRECTOR 1.00 X 0 0 0 JENNIFER KAUF DIRECTOR 1.00 X 0 0 0 EMILY KUBIK DIRECTOR 1.00 X 0 0 0 FAYE DILGEN DIRECTOR 1.00 X 0 0 0 HEATHER M FULLMER DIRECTOR 1.00 X 0 0 0 JARED STERN DIRECTOR 1.00 X 0 0 0 JEFFREY BERGER DIRECTOR 1.00 X 0 0 0 JOSHUA PAULSON DIRECTOR 1.00 X 0 0 0 KATE LEE DIRECTOR 2.00 X 0 0 0 ED VEDDER DIRECTOR 1.00 X 0 0 0 MARK BOMBACK DIRECTOR 1.00 X 0 0 0 MATTHEW HOLMES DIRECTOR 1.00 X 0 0 0 MATTHEW PRINCE DIRECTOR 3.00 X 0 0 0 MICHAEL KAHN DIRECTOR 1.00 X 0 0 0 MONIQUE SOCK DIRECTOR 1.00 X 0 0 0 RICHARD GROSSMANN DIRECTOR 1.00 X 0 0 0 ROB VERES DIRECTOR 1.00 X 0 0 0 SCOTT DIDIER DIRECTOR 1.00 X 0 0 0 STEPHEN EVANS DIRECTOR 3.00 X 0 0 0 TRACY BALDWIN DIRECTOR 1.00 X 0 0 0 WHITNEY N POLLACK DIRECTOR 1.00 X 0 0 0 MICHAEL PATRICK HUND CEO 60.00 X 352081 0 0 SARAH THYSSEN EXECUTIVE GENERAL MANAGER 0.00 40.00 X 0 86098 8038 352081 86098 8038 1 0 1 0 0 1370609 4735529 6106138 283333 283333 0 1370609 210789 -210789 -210789 EARNINGS OF AFFILIATE 900099 270077 270077 OTHER INCOME 900099 1686 1686 271763 6450445 271763 0 72544 4855644 4855644 515616 515616 351481 35148 17574 298759 273538 14980 7653 250905 42516 4198 570 37748 39794 3016 1697 35081 49714 49714 162972 162972 88404 14497 73907 349433 167222 28852 153359 15876 15876 103677 9588 6595 87494 60654 13658 472 46524 3627 3627 PAYMENT PROCESSOR FEES 60881 60881 BAD DEBT EXPENSE 48000 48000 7021827 5683281 278012 1060534 3312636 1568023 4616343 7780275 1796077 313500 2577000 3577000 60747 133686 5400 2022 2656 3378 8247984 8520293 15231 15231 234197 674316 20862871 22585702 48012 90663 2256340 4507902 2304352 4598565 X 17417275 17371137 1141244 616000 18558519 17987137 20862871 22585702 -571382 0 X 0 1 X 1 0 X 5298198 7917569 4963857 7177252 6106138 31463014 5298198 7917569 4963857 7177252 6106138 31463014 7968227 23494787 31429 115829 32398 9574 283333 472563 1602 9981 10928 466835 271763 761109 32696686 250000 0.71860 0.77630 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5400 2022 3378 3378 PRIVATELY HELD STOCK 38882 C EQUITY SECURITIES WITHOUT READILY DETERMINABLE FAIR VALUE 8481411 C 8520293 X 6750748 300303 300303 6450445 0 6450445 7322130 300303 300303 7021827 0 7021827 PART X, LINE 2: MANAGEMENT EVALUATED EBRP'S TAX POSITIONS AND CONCLUDED THAT THE EBRP HAS NOT TAKEN ANY UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH THE PROVISIONS OF FASB ASC NO. 740. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES GRANTS TO RECIPIENTS LOCATED IN THE REGION 253664 NORTH AMERICA 0 0 PROGRAM SERVICES GRANTS TO RECIPIENTS LOCATED IN THE REGION 9150 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES GRANTS TO RECIPIENTS LOCATED IN THE REGION 252802 0 0 0 0 0 0 515616 0 515616 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM REPOSITIONNING IN EPIDERMOLYSIS BULLOSA 259000 WIRE 0 EAST ASIA AND THE PACIFIC DEVELOPMENT OF A SYSTEMIC ANTIBODY THERAPY FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA. 252802 WIRE 0 0 3 0 0 1 0 0 0 PART III ACCOUNTING METHOD: PLUNGE FOR ELODIE 600586 600586 8315 VENTURES INTO CURES GALA 526252 526252 181558 6 243771 243771 20916 1370609 1370609 210789 210789 -210789 1 STANFORD UNIVERSITY 3160 PORTER DRIVE SUITE 100 PALO ALTO CA 94304 941156365 501(C)(3) 1680779 0 TO FUND RESEARCH TO FIND A CURE FOR EB UNIVERSITY OF COLORADO 13001 E 17TH PL SUITE W5130 AURORA CO 80045 846000555 501(C)(3) 1044842 0 TO FUND RESEARCH TO FIND A CURE FOR EB THOMAS JEFFERSON UNIVERSITY 601 WALNUT STREET SUITE 925E PHILADELPHIA PA 191063333 231352651 501(C)(3) 415892 0 TO FUND RESEARCH TO FIND A CURE FOR EB CENTRE FOR HUMAN GENETICS 840 MEMORIAL DRIVE SUITE 101 CAMBRIDGE MA 02139 043154223 501(C)(3) 27120 0 TO FUND RESEARCH TO FIND A CURE FOR EB CHILDREN'S HOSPITAL OF PHILADELPHIA 3401 CIVIC CENTER BLVD PHILADELPHIA PA 19104 231352166 501(C)(3) 41903 0 TO FUND RESEARCH TO FIND A CURE FOR EB PHOENIX CHILDREN'S HOSPITAL 1919 E THOMAS RD PHOENIX AZ 85016 860422559 501(C)(3) 12651 0 TO FUND RESEARCH TO FIND A CURE FOR EB COLUMBIA UNIVERSITY 615 WEST 131ST STREET MC 8741 NEW YORK NY 10027 135598093 501(C)(3) 19361 0 TO FUND RESEARCH TO FIND A CURE FOR EB CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVE CINCINNATI OH 45229 310833936 501(C)(3) 446364 0 TO FUND RESEARCH TO FIND A CURE FOR EB UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 01655 043167352 8229 0 TO FUND RESEARCH TO FIND A CURE FOR EB NORTHWESTERN UNIVERSITY 633 CLARK ST EVANSTON IL 60208 362167817 501(C)(3) 487935 0 TO FUND RESEARCH TO FIND A CURE FOR EB ASCENSION SETON MEDICAL CENTER 1201 W 38TH ST AUSTIN TX 78705 741109643 501(C)(3) 16440 0 TO FUND RESEARCH TO FIND A CURE FOR EB UNIVERSITY OF MINNESOTA 100 CHURCH STREET SE MINNEAPOLIS MN 55455 416007513 501(C)(3) 327837 0 TO FUND RESEARCH TO FIND A CURE FOR EB UNIVERSITY OF SOUTHERN CALIFORNIA 1441 EASTLAKE AVENUE ROOM 6322 LOS ANGELES CA 90033 951642394 501(C)(3) 183750 0 TO FUND RESEARCH TO FIND A CURE FOR EB AWS 410 TERRY AVENUE NORTH SEATTLE WA 98109 204938068 126555 0 TO FUND RESEARCH TO FIND A CURE FOR EB 12 3 PART I, LINE 2: EB RESEARCH PARTNERSHIP, INC. REQUIRES REPORTS ON RESEARCH PROJECTS AND PROGRESS MADE TOWARDS IDENTIFIED MILESTONES. X 0 0 0 0 0 0 0 1 0 MICHAEL PATRICK HUND CEO 264856 0 86625 0 600 0 0 0 0 0 352081 0 0 0 PART I, LINE 7 CLIENT PROVIDED IN THE CEOS BONUS TAB FORM 990, PART VI, SECTION A, LINE 2 ALEXANDER AND JAMIE SILVER HAVE A FAMILY RELATIONSHIP. EDWARD GROSSMAN AND JAMIE SILVER HAVE A FAMILY RELATIONSHIP. RICHARD GROSSMAN HAS A FAMILY REALTIONSHIP WITH JAMIE SILVER AND EDWARD GROSSMAN. MARK BOMBACK HAS A FAMILY RELATIONSHIP WITH JAMIE SILVER AND RICHARD GROSSMAN. EDDIE VEDDER AND JILL VEDDER HAVE A FAMILY RELATIONSHIP. ARI DESHE AND DANIEL DESHE HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE DRAFT OF THE FORM 990 IS REVIEWED BY THE CEO AND THEN PROVIDED TO THE FULL BOARD OF DIRECTORS AND EXECUTIVE LEADERSHIP FOR REVIEW, FEEDBACK, AND APPROVAL BEFORE IT IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE CORPORATION HAS AUTHORIZED THE EXECUTIVE COMMITTEE TO OVERSEE ALL ASPECTS OF THIS POLICY, EXCEPT (I) IF A RELATED PARTY TRANSACTION WOULD OTHERWISE REQUIRE FULL BOARD APPROVAL, THE EXECUTIVE COMMITTEE SHALL SUBMIT THE RELATED PARTY TRANSACTION TO THE BOARD FOR CONSIDERATION, PROVIDING ITS RECOMMENDATION AS TO WHETHER OR NOT TO APPROVE IT, AND (II) RATIFICATION OF A RELATED PARTY TRANSACTION THAT WAS ENTERED INTO WITHOUT REQUISITE APPROVAL SHALL REQUIRE RATIFICATION BY ACTION OF THE BOARD. IF AT ANY TIME ANY COVERED PERSON BELIEVES THAT HE OR SHE MAY HAVE AN INTEREST IN A RELATED PARTY TRANSACTION, SUCH COVERED PERSON SHALL DISCLOSE IN GOOD FAITH THE MATERIAL FACTS REGARDING SUCH INTEREST TO THE EXECUTIVE COMMITTEE. IN ADDITION, AT ANY TIME, THE CORPORATION MAY CIRCULATE A CONFLICT DISCLOSURE QUESTIONNAIRE TO ALL COVERED PERSONS REQUIRING THEM TO DISCLOSE ANY INTERESTS THEY HAVE OR MAY HAVE IN RELATED PARTY TRANACTIONS AND REMINDING THEM TO PROPERLY DISCLOSE ANY THAT MAY EVOLVE IN THE FUTURE. A CONFLICT DISCLOSURE QUESTIONNAIRE MAY ALSO BE FURNISHED TO ANY NEW DIRECTOR PRIOR TO HIS OR HER INITIAL ELECTION AND TO ANY PERSON WHO ASSUMES A POSITION AS AN OFFICE OR MAY BECOME A KEY PERSON OF THE CORPORATION AT THAT TIME. COPIES OF ANY COMPLETED AND SIGNED CONFLICT DISCLOSURE QUESTIONNAIRES SHALL BE SUBMITTED TO THE SECRETARY OF THE BOARD WHO SHALL PROVIDE A COPY OF THEM TO THE CHAIRPERSON OF THE BOARD. WHEN AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST EXISTS, THE MATERIAL FACTS REGARDING THE TRANSACTION OR ARRANGEMENT AND THE INTEREST SHALL BE PRESENTED TO THE EXECUTIVE COMMITTEE FOR A DETERMINATION AS TO WHETHER THE TRANSACTION IS FAIR, REASONABLE AND IN THE CORPORATON'S BEST INTEREST AT THE TIME OF THE DISCUSSION, TAKING INTO ACCOUNT ALL THE RELEVANT CIRCUMSTANCES, INCLUDING THE SPECIFIC RELATED PARTY TRANSACTION AND WHETHER IN THE GOOD FAITH DETERMINATION OF THE EXECUTIVE COMMITTEE THE CORPORATION COULD, WITH REASONABLE EFFORTS, OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM AN ENTITY OR INDIVUDUAL THAT WOULD NOT GIVE RISE TO A CONFLICT. IF A RELATED PARTY TRANSACTION HAS BEEN ENTERED INTO WITHOUT BEING APPROVED AS A RELATED PARTY TRANSACTION, THE CORPORATION MAY, PURSUANT TO THE FOLLOWING REQUIREMENTS, VOTE TO RATIFY SUCH A TRANSACTION. IF SUCH RATIFICATION OCCURS PRIOR TO RECEIPT OF ANY REQUEST FOR INFORMATION BY THE NEW YORK STATE ATTORNEY GENERAL REGARDING THE TRANSACTION, SUCH RATIFICATION SHALL ACT AS A DEFENSE TO AN ACTION BY THE NEW YORK STATE ATTORNEY GENERAL REGARDING SUCH TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15A THE CEO'S COMPENSATION INCLUDES A REVIEW AND APPROVAL BY THE ORGANIZATION'S GOVERNING BODY. COMPARABILITY DATA FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATION IS USED TO DETERMINE THE CEO'S COMPENSATION. ANY DECISIONS INVOLVING THE CEO'S COMPENSATION ARRANGEMENT ARE DOCUMENTED. FORM 990, PART VI, SECTION C, LINE 19 ALL ORGANIZATIONAL DOCUMENTS AND FORM 990 ARE AVAILABLE FOR INSPECTION UPON PRIOR WRITTEN REQUEST. FORM 5471 SCHEDULE C THE 2022 AUDIT REFLECTS THE AVERAGE EXCHANGE RATE FOR EACH MONTH, HOWEVER THE 990 USES THE SAME RATE USED FOR CONVERTING AUDS TO USDS FOR THE BALANCE SHEET WHICH IS THE EXCHANGE RATE AS OF DECEMBER 31, 2022. AS A RESULT, US DOLLARS PER THE 990 FOR THE EB RESEARCH AUSTRALIA INCOME STATEMENT ARE SLIGHTLY OFF FROM THE AUDIT. THE BALANCE SHEET NUMBERS PER THE 990 ARE THE SAME AS THE AUDIT. EB RESEARCH PARTNERSHIP (AUSTRALIA) LIMITED 27 BUTLER WAY LEVEL 1 TULLAMARINE VICTORIA AS 3043 FUNDING RESEARCH TO DISCOVER TREATMENTS & CURES FOR EB AS PUBLIC CHARITY EB RESEARCH PARTNERSHIP INC 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 EB RESEARCH AUSTRALIA C 358107 CASH CONTRIBUTION